TY - JOUR
T1 - Aminoglycoside/hexadecanoic acid complex lamellar core nanoparticles
AU - Khopade, Ajay J.
AU - Chitranshi, Nitin
N1 - Copyright the Author(s) 2024. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2024/12/24
Y1 - 2024/12/24
N2 - An aminoglycoside, tobramycin sulfate (TbS), was complexed with hexadecanoic acid (HdA), resulting in a TbS/HdA complex with a repeat unit of 5.3 nm of a lamellar nanostructure. The nanometer-sized TbS/HdA particles were produced using poloxamer 188 as a dispersing agent. The particles were agglomerate-free with sizes in the range of 90-450 nm. The particle size was controlled by optimizing the homogenization conditions and the concentration of poloxamer-188. The lamellar nanostructure of the TbS/HdA complex was retained in the nanoparticle cores, even after the rigorous homogenization step. These core-shell-type nanoparticles were called lamellosomes because each particle consisted of a TbS/HdA lamellar core surrounded by a crown of hydrophilic poloxamer. The ζ-potentials of nanoparticles were in the range of −20 to −26 mV and did not aggregate even after exposing them up to the concentrations of 0.2 mol L-1 NaCl. However, the nanoparticles were sensitive to the changes in the pH in terms of their aggregation or disintegration. Thus, the steric effects and ionic charge seem to be responsible for the stabilization of the nanoparticles. The TbS/HdA matrix or HdA lamella could dissolve dexamethasone up to ∼2% (w/w) without causing crystallization. The release of the entrapped drug was significantly retarded. The TbS/HdA lamellosomes could serve as aminoglycoside carriers, which can further load drugs, showing potential as a multidrug cargo.
AB - An aminoglycoside, tobramycin sulfate (TbS), was complexed with hexadecanoic acid (HdA), resulting in a TbS/HdA complex with a repeat unit of 5.3 nm of a lamellar nanostructure. The nanometer-sized TbS/HdA particles were produced using poloxamer 188 as a dispersing agent. The particles were agglomerate-free with sizes in the range of 90-450 nm. The particle size was controlled by optimizing the homogenization conditions and the concentration of poloxamer-188. The lamellar nanostructure of the TbS/HdA complex was retained in the nanoparticle cores, even after the rigorous homogenization step. These core-shell-type nanoparticles were called lamellosomes because each particle consisted of a TbS/HdA lamellar core surrounded by a crown of hydrophilic poloxamer. The ζ-potentials of nanoparticles were in the range of −20 to −26 mV and did not aggregate even after exposing them up to the concentrations of 0.2 mol L-1 NaCl. However, the nanoparticles were sensitive to the changes in the pH in terms of their aggregation or disintegration. Thus, the steric effects and ionic charge seem to be responsible for the stabilization of the nanoparticles. The TbS/HdA matrix or HdA lamella could dissolve dexamethasone up to ∼2% (w/w) without causing crystallization. The release of the entrapped drug was significantly retarded. The TbS/HdA lamellosomes could serve as aminoglycoside carriers, which can further load drugs, showing potential as a multidrug cargo.
UR - http://www.scopus.com/inward/record.url?scp=85212108115&partnerID=8YFLogxK
U2 - 10.1021/acsomega.4c09105
DO - 10.1021/acsomega.4c09105
M3 - Article
C2 - 39741839
AN - SCOPUS:85212108115
SN - 2470-1343
VL - 9
SP - 50766
EP - 50773
JO - ACS Omega
JF - ACS Omega
IS - 51
ER -